| As of Wednesday's close, CTXR had an average of 4 analyst targets pointing to a significant amount of upside potential.
In fact, with an average target of $6.00, CTXR could have over 600% potential upside from its closing valuation on Wednesday the 4th.
Could these targets mean that (Nasdaq: CTXR) is undervalued from current chart levels? -----
#3. CTXR Potential Catalyst - The Company's Commercial Launch Strategy Gets A Boost From $3.8Mn In Non-Dilutive Capital.
Citius Pharmaceuticals, Inc. Secures $3.8Mn through New Jersey Economic Development Program
Non-dilutive capital supports continued execution and value creation
CRANFORD, N.J., Feb. 24, 2026 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today announced that the Company has received $3.8Mn in non-dilutive capital through New Jersey's Technology Business Tax Certificate Transfer Program, more commonly known as the Net Operating Loss (NOL) Program, funded through the New Jersey Economic Development Authority (NJEDA).
"We are pleased to once again participate in New Jersey's NOL Program, which enables us to convert net operating losses into meaningful non-dilutive capital. As expected, this funding strengthened our balance sheet and enhances our financial flexibility as we continue executing on our strategy, including supporting the commercial launch of LYMPHIR and advancing our late-stage pipeline programs. We appreciate the continued support of the New Jersey Economic Development Authority and remain committed to disciplined capital allocation that drives long-term shareholder value while advancing important therapies for patients," stated Jaime Bartushak, Chief Financial Officer of Citius.
...
Read the full article here. -----
#4. CTXR Potential Catalyst - Revenue Begins Flowing In For The First Time ($3.9Mn Generated From Initial Sales).
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
Company reports $3.9Mn in revenue generated from initial sales in December 2025 and provides first fiscal quarter 2026 financial results
CRANFORD, N.J., Feb. 13, 2026 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal first quarter ended December 31, 2025, and provided a business update, including progress at its majority-owned subsidiary...
"I am thrilled to report that we have successfully transitioned to a revenue generating company following (the company's subsidiary's) December 2025 launch of LYMPHIR. We recorded $3.9Mn in revenue during the quarter, reflecting the initial sales ... This milestone is the result of years of focused execution designed to translate innovation into tangible value for the cutaneous T-cell community and Citius stakeholders alike. I congratulate the entire Citius team on an outstanding effort to bring LYMPHIR to market," said Leonard Mazur, Chairman and Chief Executive Officer of ... Citius Pharma.
"While we are still in the early stages of the launch, we expect momentum to build as we continue to stand up the full commercial organization and more fully deploy our technology-driven platform to expand patient access and drive market penetration. Looking ahead, we see multiple avenues for growth, including encouraging early signals from investigator-initiated studies, opp's to expand access in international markets, and the potential to build a durable oncology franchise. Most importantly, LYMPHIR now offers patients living with cutaneous T-cell lymphoma a meaningful new treatment option and a more hopeful future," added Mazur.
"We remain committed to financial stewardship to sustain this momentum, and focused execution to advance our late-stage pipeline, which includes Mino-Lok and Halo-Lido. Our goal remains to serve our community with first-in-class critical care products, and in so doing maximize long-term shareholder value," concluded Mazur.
...
Read the full article here. -----
#5. CTXR Potential Catalyst - An Interesting Chart Position Could Put CTXR On High Alert This Week!
Here was CTXR's 6-month chart at close on Wednesday.
As you can see above, CTXR closed above 4 key technical chart levels in its:
- 5-Day Simple Moving Average (SMA)
- 20-Day SMA
- 5-Day Exponential Moving Average (EMA)
- 13-Day EMA
With CTXR closing above those 4 levels, could strong chart support be developing? -----
(Nasdaq: CTXR) Recap - 5 Potential Catalysts Lead The Way!
#1. A Low Float Could Create A Volatility Storm Quickly.
#2. An Average Analyst Targets Signals Significant Upside Potential (Triple-Digit!).
#3. The Company's Commercial Launch Strategy Gets A Boost From $3.8Mn In Non-Dilutive Capital.
#4. Revenue Begins Flowing In For The First Time ($3.9Mn Generated From Initial Sales).
#5. An Interesting Chart Position Could Put CTXR On High Alert This Week! -----
Coverage is kicked-off on Citius Pharmaceuticals, Inc. (Nasdaq: CTXR).
As soon as updates pop up, I'll get them out to you quickly. Talk soon.
Sincerely, FierceAnalyst | Jaks Swift Editorial Writer
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
*FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Data is provided from third-party sources and FierceInvestor ("FI") is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. We do not provide personalized fin-ancial advice, are not finan-cial advisors, and our opinions are not suitable for all in-vest-ors.
Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 03/04/2026 and ending on 03/05/2026 to publicly disseminate information about (CTXR:US) via digital communications. Under this agreement, TD Media LLC has paid SWN Media LLC twenty thousand USD ("Funds"). To date, including under the previously described agreement, SWN Media LLC has been paid one hundred twenty seven thousand five hundred USD ("Funds"). These Funds were part of the fifty five thousand USD funds that TD Media LLC received from a third party named Sica Media LLC who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither SWN Media LLC, TD Media LLC and their member own shares of (CTXR:US).
Please see important disclosure information here: https://fierceinvestor.com/disclosure/ctxr-c7pxt/#details | 
Tidak ada komentar:
Posting Komentar